Document is current
Any future updates will be listed below
-
Authors
Howard, Sarah Anne
Tsuruta, James K.
Trujillo, Andres Prieto
Shrivastava, Roopali
Cohen, Ava
Sellers, Rani S.
Hamil, Katherine G.
O’Rand, Michael G.
Benhabbour, S. Rahima https://orcid.org/0000-0002-4738-5871
-
Funding
Funding for this research was provided by:
Male Contraception Initiative (David Sokal Award)
National Science Foundation Graduate Research Fellowship Program (DGE-2040435)
North Carolina Biotech Center Institutional Support Grant (2017-IDG-1025)
National Institutes of Health (1UM2AI30836-01)
NIH-NICHD (P50 HD103573)
- License Information
-
More Information
Article History
Accepted: 30 April 2025
First Online: 27 May 2025
Declarations
:
: The animal study protocol was approved by the Institutional Animal Care and Use Committee at the University of North Carolina (protocol number/IACUC ID 24–080).
: N/A.
: N/A
: Michael G. O’Rand has stock ownership in Eppin Pharma Inc. Dr. O’Rand receives no salary from Eppin Pharma. Katherine G. Hamil is a full-time employee of Eppin Pharma and has stock ownership in the company. SRB is inventor on a patent describing the Injectable Polymer Based Drug Formulation for Ultra-Long-Acting Drug Delivery. The remaining authors declare that they have no competing interests.
